New York, NY – An iron-binding drug that is already approved for treatment of other diseases could provide a novel way to attack ovarian tumors, according to a new study led by Weill Cornell Medicine researchers. The preclinical study, which combined the analysis of human ovarian tumors and animal models...
Latest News
Creating a strategy to discontinue eculizumab in patients with atypical hemolytic uremic syndrome (aHUS) is reasonable and safe and improves quality of life, according to research in Blood. The strategy should be based on complement genetics. Eculizumab has drastically improved outcomes for patients with aHUS. There’s no clearly defined optimal duration...
ROCKVILLE, Md. and SHANGHAI — I-Mab (Nasdaq: IMAB) (the “Company”), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, and HI-Bio, a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated...
PARSIPPANY, N.J. — Ferring Pharmaceuticals announced today it is presenting the methodology for the ADSTILADRIN in BLadder cancEr (ABLE-41) Real World Evidence (RWE) study at the 20th Annual American Society of Clinical Oncologists Genitourinary Cancers Symposium (ASCO GU). ABLE-41 (NCT06026332) is an ongoing Phase 4 observational study evaluating the effectiveness,...
Hong Kong – A new study finds that very few patients diagnosed with type 2 diabetes are able to achieve normal blood glucose levels through weight loss alone. A team led by Andrea Luk of the Chinese University of Hong Kong, reported these findings in the open access journal PLOS Medicine....
SAN FRANCISCO, Calif. — FibroGen, Inc. announced graduation and completion of the pamrevlumab experimental arm in the Pancreatic Cancer Action Network’s (PanCAN) Precision PromiseSM Phase 2/3 adaptive platform trial, which evaluates pamrevlumab in combination with the chemotherapy treatments gemcitabine and nab-paclitaxel for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Topline...
Greenwich, CT – The Fibrolamellar Cancer Foundation is pleased to announce that it has funded a new study directed by Roshni Dasgupta, MD of the Cincinnati Children’s Hospital Medical Center (CCHMC). Dr. Dasgupta is a leader in surgical oncology and the chair of the Pediatric Surgical Oncology Research Collaborative (PSORC)....
Port Elizabeth, South Africa – Fibrous dysplasia is a benign tumour-like condition in which normal bone is replaced by structurally poor fibro-osseous lamellar bone. It occurs as a result of an early embryonic postzygotic activating mutation of the GNAS gene which manifests clinically in a wide spectrum of disease. Fibrous...
COLUMBUS, Ohio – Scientists are focusing on a new concept in fighting airborne pathogens by manipulating what is called the “switching time,” the point at which a highly regulated immune response gives way to powerful cells that specialize in fighting a specific invading bug. In the case of tuberculosis, Ohio...
Tuberculosis should not be a death sentence in 2009. It wasn’t for me nearly 70 years ago after I contracted the disease in the Terezin concentration camp in what was then Czechoslovakia. But today, nearly 2 million people die from TB each year, an unconscionable number of lives lost to...